Novo Nordisk Stock: Deal with Hims & Hers, Analyst Downgrade & Future Concerns
The pharmaceutical giant Novo Nordisk is navigating a complex landscape of commercial wins and growing analyst skepticism, a duality that encapsulates the company’s current position: a robust core business tempered by increasing doubts about its long-term trajectory. Recent developments, including a significant partnership with telehealth provider Hims & Hers and a downgrade from a leading … Read more